Who is Calcilytix?

Calcilytix is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, hypothesized to restore normal serum calcium and lower urine calcium in patients with abnormal Calcium-Sensing Receptors (CaSRs).

Calcilytix is led by a team of industry veterans who have been responsible for developing over 30 molecules through Initial New Drug (IND) applications and more than 10 approved drugs. Together with physicians and patients, we aim to develop an effective treatment option for patients with hypopara and Autosomal Dominant Hypocalcemia Type 1 (ADH1).